Survodutide — Lilipeptide

Survodutide

SKU: LILI-survodutide
Brand:
Brand Lilipeptide600 followers
Original price was: $450.00.Current price is: $420.00.

In Stock

Also coded BI 456906, an investigational dual agonist of glucagon and GLP-1 receptors under late-stage clinical evaluation for obesity and fatty liver disease; not an approved medicine.

  • Third-party report: Not on file yet
  • Dispatches from: China
Bulk pricingCombine any Lilipeptide products: each kit from this vendor counts toward your discount tier.
  1. 1–4 kits$420.00full price
  2. 5+ kits$399.005% off
  3. 10+ kits$378.0010% off
  4. 20+ kits$369.6012% off
  5. 50+ kits$357.0015% off
  6. 100+ kits$336.0020% off
ß

Minimum order $100.00 across all brands, before the escrow fee.

◆
Escrow-protected purchaseYour payment is held by us — the brand is only paid after you confirm delivery.
↺
Refund if not deliveredOpen a claim from your order page; upheld claims are refunded to your Escrow Wallet.
✓
Sold by LilipeptideVetted vendor · ships from China
⚗
Lab testingNo public report for this listing yet. We can request the batch COA before you order. What to test →

For research use only. Not for human consumption. Not medical advice.

Log in to watch this price

This Lilipeptide listing is a kit of Survodutide, dispatched from China. You pay $420.00 for the kit. Funds sit in escrow until delivery is confirmed, then they are released to Lilipeptide.

This listing: Lilipeptide Survodutide

Also sold by
Uther Peptide 10mg $230.00 · HK Peptide 10mg $300.00 · TFC Peptides 10mg $210.00 · Jinlu Peptides 10mg $620.10

Lab testing

There is no public lab report for this listing yet. We can ask the brand for the batch COA before you order. Many buyers also split an independent HPLC test with others who bought the same batch.

Request the batch COA · How group testing works

Bought through escrow: the brand is only paid after you confirm delivery. If the parcel never arrives, or an independent test shows the wrong compound or a significant under-fill, open a claim before releasing payment.

About Survodutide

Boehringer Ingelheim brought survodutide forward after early discovery with Zealand Pharma. It is a lipid-modified, engineered peptide that engages the glucagon receptor and the GLP-1 receptor at once, and the attached fatty acid slows its removal from the bloodstream. It sits within the family of multi-agonist incretin-style peptides but, unlike tirzepatide, does not touch the GIP receptor. Its chemistry reflects a wider shift in metabolic research toward single molecules that hit several targets.

Areas of study

Why combine two receptors? The GLP-1 arm is studied for eating less, slower stomach emptying and insulin release that depends on glucose. The glucagon arm acts chiefly in the liver, where it is investigated for greater fat oxidation, lower liver fat and a rise in energy expenditure; alone, though, it pushes blood sugar up. GLP-1 activity is expected to counter that. The ratio of the two actions is a central design choice, and their relative contributions are not fully worked out.

Where Survodutide stands

Mid-stage studies in obesity and in metabolic-dysfunction-associated steatohepatitis reported larger drops in weight and liver fat than placebo, with digestive complaints topping the adverse-event list. Pivotal programs are described as ongoing. No agency has approved the drug, long-term safety data are still accumulating, and a research vial has no tie to what the sponsor supplies in trials.

Lab verification

The mass reading should reflect the intact lipidated molecule; a signal at the lipid-free backbone mass would suggest that the side chain never attached. Impurities with near-identical sequences or partial acylation are typical in this family, so inspect the HPLC trace rather than a bare number. Look for net content and an even, pale solid.

No third-party report is attached to this listing yet. The lab reports directory shows which brands publish testing, and Testing 101 explains how to commission your own.

Kit details

Active compound
Survodutide
Also known as
BI 456906
Peptide class
Investigational dual glucagon/GLP-1 receptor agonist
Form
Lyophilized (freeze-dried) powder
Dispatches from
China
Third-party report
Not on file yet

Keeping the vials

Store lyophilized vials cold, dry and dark until they are needed. After reconstitution, refrigerate and avoid letting the solution warm up repeatedly; your protocol should define how long it remains usable.

Common questions

What would a glucagon-receptor agonist be doing in a weight-related peptide?

Though known for lifting blood sugar, glucagon also drives fat breakdown and energy use in the liver. The molecule is built to harness that while GLP-1 action balances glucose, which is why liver fat is such a prominent trial endpoint.

How can I trace the literature?

Search both the name and the code BI 456906. Boehringer Ingelheim runs development, building on work with Zealand Pharma, and older registry entries or papers often carry only the code. Using both names avoids missing earlier records.

What exactly is in this kit?

No lab report is attached yet, so the label figures have not been independently confirmed.

When is Lilipeptide paid?

It stays in escrow until you confirm delivery; only then is it released to Lilipeptide. If the order is missing or not as described, open a claim before releasing and the held amount can be refunded to your Escrow Wallet.

For in-vitro and laboratory research only. Not for human or veterinary use and not a replacement for any prescribed medicine. Nothing here is medical advice.

Reviews

There are no reviews yet.

0.00

Average of 0 reviews

0 reviews
0 reviews
0 reviews
0 reviews
0 reviews
Be the first to review “Survodutide”

Your email address will not be published. Required fields are marked *

12%
Thymosin Alpha-1
Original price was: $125.00.Current price is: $110.00.

In Stock

12%
DSIP
Original price was: $65.00.Current price is: $57.00.

In Stock

15%
LL37
Original price was: $130.00.Current price is: $110.00.

In Stock